Dr. Kenneth Pienta Laboratory


April 18, 2013:  Dr. Pienta elected to the Board of Curis, Inc.  Curis is a drug development company that is committed to leveraging its innovative signaling pathway drug technologies to seek to create new targeted small molecule drug candidates for cancer. Curis is building upon its previous experiences in targeting signaling pathways, including in the Hedgehog pathway, in its effort to develop proprietary targeted cancer programs.

April 1, 2013:  Dr. Pienta joins the Princeton Physical Sciences in Oncology Center (PPS-OC).  The Princeton Physical Sciences-Oncology Center (PPS-OC) is an interdisciplinary research center which seeks to undertake innovative new approaches to understanding the physical laws that govern the emergence and behavior of cancer. The PPS-OC brings together a team of experts from the fields of physics, engineering, chemistry, biochemistry and oncology in order to catalyze a fundamentally new understanding of cancer, based on a physical sciences-based thematic approach. The PPS-OC includes collaborations with partnering institutions: the University of California-San Francisco, the Johns Hopkins University, the University of California-Santa Cruz, and the Salk Institute for Biological Studies.

March 1, 2013:  Dr. Pienta named the Donald S. Coffey Professor of Urology and Professor of Oncology and Pharmacology and Molecular Sciences at the Johns Hopkins University School of Medicine.

February 3, 2013:  Dr. Pienta joins CollabRx as a Prostate Cancer Editorial Board Member. CollabRx is a data analytics company that uses cloud-based expert systems to inform healthcare decision-making by aggregating and contextualizing the world's knowledge on molecular medicine with specific insights from the nation's top clinical experts.

January 28, 2013:  Dr. Pienta to join the faculty of the Johns Hopkins School of Medicine as Director of Research for the Brady Urological Institute on March 1, 2013.

October 18, 2012:  Dr. Pienta gives the William Scott Lecture at Johns Hopkins School of Medicine

September 2012:  Dr. Pienta named among the top 1% of physicians by US News and World Report.

September 2012:  Dr. Pienta joins the National Cancer Advisory Board for Frederick National Labs

August 2012:  The University of Michigan awarded a Stand-Up-To-Cancer (SU2C) grant to study molecular changes in advanced prostate cancer.

January 2012:   Dr. Pienta announced as Associate Vice President for Research,       Health  Sciences, for the University of Michigan

2011                Induction into the Society of Scholars of the Johns Hopkins University

2011                Alfred Taubman Scholar Award – Taubman Medical Research Institute – University of Michigan

2011                Inclusion in "League of Research Excellence" – University of Michigan Medical School

2011                Inclusion in "America's Top Doctors"

2011                Inclusion in "Best Doctors" in America

2011                Inclusion in "America's Top Doctors for Cancer"

2011                Inclusion in Who's Who in Healthcare – "Montclair Who's Who"

2010                Inclusion in "Patients' Choice Award"

2009                American Urological Association Distinguished Mentor of the Year Award

2009                Prostate Cancer Foundation Core Values Award

© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved. Disclaimer
Email: webmaster@urology.jhu.edu | 600 North Wolfe Street, Baltimore, Maryland 21287

urology second opinion urology second opinion